Developing imaging technologies capable of identifying unstable atheromatous plaques in vivo is a major issue of clinical cardiovascular research. These techniques would allow an earlier surgical or medical therapy before acute ischemic syndromes [1]. Plaque stability and its counterpart i.e. vulnerability are depending on the relative amount and morphology of its principal components: lipid core and fibrous cap [2-5]. To evaluate plaque composition, we need to develop biochemical imaging techniques that estimate plaque vulnerability and predict future clinical events, which depend more on plaque composition rather than morphological parameters (such as the degree of stenosis described by conventional imaging techniques such as angiography). Among these new techniques, MRI realizes a true tissue characterization for it is based on a three-dimensional encoding of biochemical informations. Furthermore, it is a non invasive, non radioactive technology, which permits as many repetitive examinations as needed without the risks of arterial puncture (peripheral emboli, arterial dissection or occlusion). It also avoids the risk of iodinated contrast agents on renal function or anaphylactic reaction. Evaluating carotid atherosclerosis and coronary